- Home
- JGH vs ABEO Comparison
JGH vs ABEO Comparison
Compare JGH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | ABEO |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.3M | 399.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | JGH | ABEO |
|---|---|---|
| Price | $11.77 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 58.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $11.71 | $4.00 |
| 52 Week High | $13.70 | $7.65 |
Technical Indicators
Market Signals| Indicator | JGH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 19.18 | 41.31 |
| Support Level | N/A | $5.23 |
| Resistance Level | $12.92 | $5.55 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 1.32 | 38.65 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.